1026 related articles for article (PubMed ID: 26395532)
21. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.
Wook Hong S; Kim YG; Ye BD
Immunotherapy; 2020 Jun; 12(9):609-623. PubMed ID: 32517574
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
[TBL] [Abstract][Full Text] [Related]
23. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.
Parigi TL; D'Amico F; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2021 Jan; 21(1):37-46. PubMed ID: 32799561
[TBL] [Abstract][Full Text] [Related]
24. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
[No Abstract] [Full Text] [Related]
25. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
26. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
Smits LJT; van Esch AAJ; Derikx LAAP; Boshuizen R; de Jong DJ; Drenth JPH; Hoentjen F
Inflamm Bowel Dis; 2019 Jan; 25(1):172-179. PubMed ID: 29947795
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
Schellekens H; Lietzan E; Faccin F; Venema J
Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
[TBL] [Abstract][Full Text] [Related]
28. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
Tweehuysen L; van den Bemt BJF; van Ingen IL; de Jong AJL; van der Laan WH; van den Hoogen FHJ; den Broeder AA
Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
[TBL] [Abstract][Full Text] [Related]
29. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
[TBL] [Abstract][Full Text] [Related]
30. A review of CT-P13: an infliximab biosimilar.
McKeage K
BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Clinical Outcomes After Switching from Remicade
Smits LJT; Grelack A; Derikx LAAP; de Jong DJ; van Esch AAJ; Boshuizen RS; Drenth JPH; Hoentjen F
Dig Dis Sci; 2017 Nov; 62(11):3117-3122. PubMed ID: 28667429
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
[TBL] [Abstract][Full Text] [Related]
33. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
34. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
35. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
36. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
Annese V; Vecchi M;
Dig Liver Dis; 2014 Nov; 46(11):963-8. PubMed ID: 25139379
[TBL] [Abstract][Full Text] [Related]
37. The use of biosimilars in paediatric inflammatory bowel disease.
Jongsma MME; Vulto A; de Ridder L
Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
[TBL] [Abstract][Full Text] [Related]
38. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
Argüelles Arias F; Hinojosa Del Val J; Vera Mendoza I
Rev Esp Enferm Dig; 2018 Jun; 110(6):407. PubMed ID: 29527903
[TBL] [Abstract][Full Text] [Related]
39. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
Danese S; Fiorino G
Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
[TBL] [Abstract][Full Text] [Related]
40. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
